These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20829621)

  • 21. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).
    Chu JW; Matthias DF; Belanoff J; Schatzberg A; Hoffman AR; Feldman D
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3568-73. PubMed ID: 11502780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology of Cushing's disease.
    Fehm HL; Voigt KH
    Pathobiol Annu; 1979; 9():225-55. PubMed ID: 225710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mifepristone (Korlym) for Cushing's syndrome.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):46-7. PubMed ID: 22683927
    [No Abstract]   [Full Text] [Related]  

  • 24. [Psychic symptoms and personality of 50 patients with Cushing's syndrome (author's transl)].
    Mazet P; Simon D; Luton JP; Bricaire H
    Nouv Presse Med; 1981 Aug 29-Sep 5; 10(31):2565-70. PubMed ID: 7279633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Merits and pitfalls of mifepristone in Cushing's syndrome.
    Castinetti F; Fassnacht M; Johanssen S; Terzolo M; Bouchard P; Chanson P; Do Cao C; Morange I; Picó A; Ouzounian S; Young J; Hahner S; Brue T; Allolio B; Conte-Devolx B
    Eur J Endocrinol; 2009 Jun; 160(6):1003-10. PubMed ID: 19289534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoid action and the clinical features of Cushing's syndrome.
    Yanovski JA; Cutler GB
    Endocrinol Metab Clin North Am; 1994 Sep; 23(3):487-509. PubMed ID: 7805650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mifepristone (RU 486) in Cushing's syndrome.
    Johanssen S; Allolio B
    Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical profile of memory impairment in humans due to endogenous glucocorticoid excess.
    León-Carrión J; Atutxa AM; Mangas MA; Soto-Moreno A; Pumar A; Leon-Justel A; Martín-Rodriguez JF; Venegas E; Domínguez-Morales MR; Leal-Cerro A
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):192-200. PubMed ID: 18702680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychiatric disorders associated with Cushing's syndrome.
    Bratek A; Koźmin-Burzyńska A; Górniak E; Krysta K
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S339-43. PubMed ID: 26417792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension in Cushing's syndrome: from pathogenesis to treatment.
    Cicala MV; Mantero F
    Neuroendocrinology; 2010; 92 Suppl 1():44-9. PubMed ID: 20829617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome.
    Oosterhuis JK; van den Berg G; Monteban-Kooistra WE; Ligtenberg JJ; Tulleken JE; Meertens JH; Zijlstra JG
    Neth J Med; 2007 Jun; 65(6):215-7. PubMed ID: 17587649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of mifepristone in the treatment of neuropsychiatric disorders.
    DeBattista C; Belanoff J
    Trends Endocrinol Metab; 2006 Apr; 17(3):117-21. PubMed ID: 16530421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychiatric and neurocognitive consequences of endogenous hypercortisolism.
    Piasecka M; Papakokkinou E; Valassi E; Santos A; Webb SM; de Vries F; Pereira AM; Ragnarsson O
    J Intern Med; 2020 Aug; 288(2):168-182. PubMed ID: 32181937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications.
    Gold PW; Loriaux DL; Roy A; Kling MA; Calabrese JR; Kellner CH; Nieman LK; Post RM; Pickar D; Gallucci W
    N Engl J Med; 1986 May; 314(21):1329-35. PubMed ID: 3010108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states.
    Pecori Giraldi F; Pivonello R; Ambrogio AG; De Martino MC; De Martin M; Scacchi M; Colao A; Toja PM; Lombardi G; Cavagnini F
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):251-7. PubMed ID: 17223996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
    Feelders RA; Hofland LJ; de Herder WW
    Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension in Cushing's syndrome.
    Magiakou MA; Smyrnaki P; Chrousos GP
    Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):467-82. PubMed ID: 16980206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of postoperative ACTH levels as a marker for successful transsphenoidal microsurgery in Cushing's disease.
    Flitsch J; Knappe UJ; Lüdecke DK
    Zentralbl Neurochir; 2003; 64(1):6-11. PubMed ID: 12582940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.